Spyre Therapeutics, Inc. (SYRE) — 10-Q Filings
All 10-Q filings from Spyre Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Spyre Narrows Q3 Loss on CVR Revaluation, Asset Sale
— Nov 4, 2025 Risk: medium
Spyre Therapeutics, Inc. reported a net loss of $11.183 million for the three months ended September 30, 2025, a significant improvement from the $69.028 millio -
Spyre Therapeutics Narrows Q2 Loss to $33M Amid R&D Focus
— Aug 5, 2025 Risk: high
Spyre Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company incurred a -
Spyre Therapeutics Files Q1 2025 10-Q
— May 8, 2025 Risk: medium
Spyre Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Aeglea BioTherapeutics, Inc. until March 11, 2015, -
Spyre Therapeutics Files Q3 2024 10-Q
— Nov 7, 2024 Risk: medium
Spyre Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Aeglea BioTherapeutics, Inc. until March 11, 20 -
Spyre Therapeutics Files Q2 2024 10-Q
— Aug 7, 2024 Risk: medium
Spyre Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly Aeglea BioTherapeutics, Inc., reported financial results for -
Spyre Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
— May 9, 2024 Risk:
Spyre Therapeutics, Inc. (SYRE) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Spyre Therapeutics, Inc. filed its quarterly report (10-Q) on May 9
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX